Sales of antiarrhythmic medicines in Italy are anticipated to incrementally grow over the forecast period, increasing from 85.1 million euros in 2024 to 88.3 million euros by 2028. This represents a consistent year-on-year growth rate of roughly 0.94%. Assuming steady market conditions, the compound annual growth rate (CAGR) stands at approximately 0.93%. In 2023, the actual sales value should be considered around the 2023 forecast estimation, given no available data for this year. Market dynamics remain favorable for sustained modest growth.
Future trends to watch for include:
- Potential regulatory changes impacting market dynamics.
- Technological advancements in drug formulation and delivery.
- Emerging competition from generic alternatives.
- Demographic shifts influencing market demand.
